Sartorius Stedim Biotech shares admitted to the CAC Next 20 index

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, will soon be listed on the French stock index CAC Next 20 and therefore also on the CAC Large 60 index. According to the decision of the Euronext Expert Indices Committee (Conseil Scientifique des Indices), the Sartorius Stedim Biotech share will be included in the above mentioned indices effective September 18 after closing, as Euronext Paris announced yesterday evening. The CAC Next 20 index consists of the 20 highest ranking companies that, based on a combination of their rankings on free-float-adjusted market capitalization and stock exchange turnover, are not included in the French benchmark index CAC 40. These two indices form the CAC Large 60 index.

“Sartorius Stedim Biotech has experienced a dynamic development for a number of years. Through strong organic growth and our successful acquisition strategy, we have created value for customers, employees and investors. We are pleased that the performance of our share has now resulted in admission to the CAC Next 20,” said Joachim Kreuzburg, Chairman of the Board of Directors and CEO.